ABUSE POTENTIAL OF VARIOUS OPIOID MEDICATIONS

被引:13
作者
BROOKOFF, D
机构
[1] Department of Medical Education, Methodist Hospitals of Memphis, Memphis, Tennessee, 38104
关键词
NARCOTICS; OPIOIDS; DRUG ABUSE; PRESCRIBING; CONTROLLED-RELEASE MEDICATIONS;
D O I
10.1007/BF02598290
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The abuse potentials of various narcotic medications were assessed by surveying 130 hospital patients who admitted to having abused prescription narcotics within the preceding six months. 85% of the subjects surveyed reported having tried controlled-release narcotic preparations for abuse purposes and 60% reported that they were of little or no use. To obtain another index of abuse potential, the author asked the subjects to estimate the street prices of various medications. The street prices of controlled-release formulations were lower than those of other narcotic medications and those of some uncontrolled nonnarcotic medications. These results suggest that controlled-release narcotic formulations may have a lower potential for abuse than do other narcotic medications. In situations where there is concern about potential abuse or diversion of prescribed narcotics, controlled-release preparations may be an appropriate alternative to high-peaking, rapid-onset opioid formulations.
引用
收藏
页码:688 / 690
页数:3
相关论文
共 16 条
  • [1] Sigler K.A., Guernsey B.G., Ingrim N.B., Buesing A.A., Effect of triplicate prescription law on prescribing of schedule II drugs, Am J Hosp Pharm, 42, (1985)
  • [2] Weintraub M., Singh S., Byrne L., Maharaj K., Guttmacher L., Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations, JAMA, 266, (1991)
  • [3] Zullich S.G., Grasela T.H., Fiedler-Kelly J.B., Gengo F.M., Impact of triplicate prescription program on psychotropic prescribing patterns in long-term care facilities, Ann Pharmacother, 26, (1992)
  • [4] Cooper J.R., Czechowicz D.J., Peterson R.C., Molinari S.P., Prescription drug diversion control and medical practice, JAMA, 268, (1992)
  • [5] Glass R.M., Benzodiazepine prescription regulation: autonomy and outcome, JAMA, 266, (1991)
  • [6] Stimmel B., Pain, Analgesia and Addiction: The Pharmacologic Treatment of Pain, (1983)
  • [7] Khojasteh A., Evans W., Reynolds R.D., Controlled-release oral morphine sulfate in the treatment of cancer pain with pharmacokinetic correlation, J Clin Oncol, 5, (1987)
  • [8] Jasinski D.R., Assessment of the abuse potentiality of morphinelike drugs, Handbook of Experimental Pharmacology, (1977)
  • [9] Roberts J., In Focus, Emerg Med News, 6, pp. 3-5, (1992)
  • [10] Crews J.C., Denson D.D., Recovery of morphine from a controlled-release preparation, Cancer, 66, (1990)